[go: up one dir, main page]

WO2000049144A3 - Proteines fixatrices pyk2 - Google Patents

Proteines fixatrices pyk2 Download PDF

Info

Publication number
WO2000049144A3
WO2000049144A3 PCT/US2000/004647 US0004647W WO0049144A3 WO 2000049144 A3 WO2000049144 A3 WO 2000049144A3 US 0004647 W US0004647 W US 0004647W WO 0049144 A3 WO0049144 A3 WO 0049144A3
Authority
WO
WIPO (PCT)
Prior art keywords
pyk2 binding
binding proteins
pyk2
protein
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/004647
Other languages
English (en)
Other versions
WO2000049144A2 (fr
Inventor
Sima Lev
Joseph Schlessinger
Alon Chen
John Hernandez
Ricardo Martinez
Gregory D Plowman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sugen LLC
Original Assignee
Sugen LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sugen LLC filed Critical Sugen LLC
Priority to CA002362943A priority Critical patent/CA2362943A1/fr
Priority to JP2000599869A priority patent/JP2003510010A/ja
Priority to AU32422/00A priority patent/AU3242200A/en
Priority to EP00910308A priority patent/EP1157104A2/fr
Publication of WO2000049144A2 publication Critical patent/WO2000049144A2/fr
Publication of WO2000049144A3 publication Critical patent/WO2000049144A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne de nouvelles protéines fixatrices Pyk2, des séquences nucléotidiques codant pour ces nouvelles protéines, ainsi que divers produits et méthodes utilisés dans le diagnostic et le traitement de diverses maladies et divers états pathologiques liés à la protéine fixatrice Pyk2 et à la protéine kinase. Grâce à l'utilisation de systèmes bio-informatiques, deux membres mammaliens de la famille de la protéine fixatrice Pyk2 ont été identifiés et leur structure protéique déterminée.
PCT/US2000/004647 1999-02-22 2000-02-18 Proteines fixatrices pyk2 Ceased WO2000049144A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002362943A CA2362943A1 (fr) 1999-02-22 2000-02-18 Proteines fixatrices pyk2
JP2000599869A JP2003510010A (ja) 1999-02-22 2000-02-18 Ｐｙｋ２結合蛋白質
AU32422/00A AU3242200A (en) 1999-02-22 2000-02-18 Pyk2 binding proteins
EP00910308A EP1157104A2 (fr) 1999-02-22 2000-02-18 Proteines fixatrices pyk2

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12112599P 1999-02-22 1999-02-22
US60/121,125 1999-02-22

Publications (2)

Publication Number Publication Date
WO2000049144A2 WO2000049144A2 (fr) 2000-08-24
WO2000049144A3 true WO2000049144A3 (fr) 2001-02-15

Family

ID=22394720

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/004647 Ceased WO2000049144A2 (fr) 1999-02-22 2000-02-18 Proteines fixatrices pyk2

Country Status (5)

Country Link
EP (1) EP1157104A2 (fr)
JP (1) JP2003510010A (fr)
AU (1) AU3242200A (fr)
CA (1) CA2362943A1 (fr)
WO (1) WO2000049144A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005002573A2 (fr) * 2003-06-06 2005-01-13 Elan Pharmaceuticals, Inc. Methodes d'utilisation de modulateurs de tyrosine kinase 2 riche en proline
US7977462B2 (en) * 2007-04-19 2011-07-12 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998007870A1 (fr) * 1996-08-23 1998-02-26 Beth Israel Deaconess Medical Center, Inc. Nouvelles molecules de signalisation raftk et leurs utilisations
WO1998016639A1 (fr) * 1996-10-11 1998-04-23 Sugen, Inc. Proteines rdgb
WO1998026054A2 (fr) * 1996-12-11 1998-06-18 Sugen, Inc. Produits et procedes en relation avec la pyk2
WO1998036065A1 (fr) * 1997-02-14 1998-08-20 Dana-Farber Cancer Institute Facteurs de stimulation de la differentiation et utilisations de ces facteurs

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998007870A1 (fr) * 1996-08-23 1998-02-26 Beth Israel Deaconess Medical Center, Inc. Nouvelles molecules de signalisation raftk et leurs utilisations
WO1998016639A1 (fr) * 1996-10-11 1998-04-23 Sugen, Inc. Proteines rdgb
WO1998026054A2 (fr) * 1996-12-11 1998-06-18 Sugen, Inc. Produits et procedes en relation avec la pyk2
WO1998036065A1 (fr) * 1997-02-14 1998-08-20 Dana-Farber Cancer Institute Facteurs de stimulation de la differentiation et utilisations de ces facteurs

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ANDREEV J ET AL.: "Identification of a new Pyk2 target protein with Arf-GAP activity", MOLECULAR AND CELLULAR BIOLOGY, vol. 19, no. 3, March 1999 (1999-03-01), pages 2338 - 2350, XP002145146 *
BROWN M T ET AL.: "Regulation, substrates and functions of src", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1287, no. 2-3, 7 June 1996 (1996-06-07), pages 121 - 149, XP000938413 *
DATABASE TREMBL EMBL; 1 June 1998 (1998-06-01), ISHIKAWA K ET AL.: "KIAA0400", XP002145148 *
ISHIKAWA K ET AL.: "Prediction of the coding sequences of unidentified human genes. VIII. 78 new cDNA clones from brain which code for large proteins in vitro", DNA RESEARCH, vol. 4, no. 5, 31 October 1997 (1997-10-31), pages 307 - 313, XP002066665 *
LEV S ET AL.: "Identification of a novel family of targets of PYK2 related to Drosophila retinal degeneration B (rdgB) protein", MOLECULAR AND CELLULAR BIOLOGY, vol. 19, no. 3, March 1999 (1999-03-01), pages 2278 - 2288, XP002145147 *
SCHLAEPFER D D ET AL.: "Integrin signalling and tyrosine phosphorylation: just the FAKs?", TRENDS IN CELL BIOLOGY, vol. 8, no. 4, April 1998 (1998-04-01), pages 151 - 157, XP000938480 *
WENG Z ET AL.: "Identification of Src, Fyn, and Lyn SH3-binding proteins: Implications for a function of SH3 domains", MOLECULAR AND CELLULAR BIOLOGY, vol. 14, no. 7, 1 July 1994 (1994-07-01), pages 4509 - 4521, XP000652941 *

Also Published As

Publication number Publication date
WO2000049144A2 (fr) 2000-08-24
EP1157104A2 (fr) 2001-11-28
CA2362943A1 (fr) 2000-08-24
AU3242200A (en) 2000-09-04
JP2003510010A (ja) 2003-03-18

Similar Documents

Publication Publication Date Title
EP0837131A3 (fr) Composé contenant la protéine liant la fibronectine obtenu à partir de Staphylococcus
WO2004006838A3 (fr) Nouvelles kinases
MXPA02002384A (es) Polipeptidos similares al factor de crecimiento de fibroblastos.
WO2000073469A3 (fr) Proteines kinases
WO2000031235A3 (fr) Sequences nucleotidiques et proteiques de gene nogo et procedes reposant sur ces sequences
WO2001038503A3 (fr) Nouvelles proteines kinases humaines et enzymes analogues
WO2001083782A3 (fr) Nouvelles proteases
WO1996034953A3 (fr) Variants de cd16-ii
WO2001012659A3 (fr) Sequence d'adn humain
WO1997044356A3 (fr) Test diagnostique de detection de la schizophrenie faisant appel a de la miacine
WO1997008314A3 (fr) Facteur de liaison telomerique, son utilisation diagnostique et therapeutique
WO2001046394A3 (fr) Proteines phosphatases mammiferes
WO1998006841A3 (fr) Deux proteines humaines du genre nsp
WO1998011234A3 (fr) Proteines kinases humaines
WO1998011232A3 (fr) Proteine humaine de type nm23
WO2001066594A3 (fr) Nouvelles proteines kinases humaines et enzymes analogues de proteines kinases
HK1048480A1 (zh) 編碼人α-CT型鈣通道的DNA
WO2004096856A3 (fr) Famille de proteines secretees
WO2000049144A3 (fr) Proteines fixatrices pyk2
WO2004096976A3 (fr) Compositions de composes exprimes par la rate (spex) et leurs procedes d'utilisation
WO2000047723A3 (fr) Nouvelles proteines
HK1052726A1 (zh) 人类蛋白激酶及类似蛋白激酶的酵素
WO1998031805A3 (fr) Proteines humaines se liant au zinc
WO2001036478A3 (fr) Methodes et compositions se rapportant a des polypeptides et a des polynucleotides similaires au facteur bactericide augmentant la permeabilite
WO2001092491A3 (fr) Phosphatases de proteine de mammifere

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2362943

Country of ref document: CA

Ref country code: CA

Ref document number: 2362943

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 599869

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000910308

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000910308

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000910308

Country of ref document: EP